ReviewVascular health and risk management2006
Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation.
Review in Vascular health and risk management, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Pharmacological interventions to prevent cardiotoxicity in patients undergoing anthracycline-based chemotherapy: a network meta-analysis.Frontiers in cardiovascular medicine · 2025Pooled it
- Differential Metabolic Effects of Beta-Blockers: an Updated Systematic Review of Nebivolol.Current hypertension reports · 2017Pooled it
- Model-informed dose optimization of carvedilol and nebivolol in cirrhotic patients: a pilot randomized clinical study.Scientific reports · 2026Trial
- Trial
- Blood pressure effects of combined β-blocker and angiotensin-converting enzyme inhibitor therapy compared with the individual agents: a placebo-controlled study with nebivolol and lisinopril.Journal of clinical hypertension (Greenwich, Conn.) · 2012Trial
- Does nebivolol prevent contrast-induced nephropathy in humans?Clinical cardiology · 2012Trial
- Nebivolol versus Carvedilol or Metoprolol in Patients Presenting with Acute Myocardial Infarction Complicated by Left Ventricular Dysfunction.Medical principles and practice : international journal of the Kuwait University, Health Science CentreTrial
- Physicians' attitudes toward beta-blockers for the treatment of hypertension in Italy, Poland, and Turkey.Journal of clinical hypertension (Greenwich, Conn.) · 2024Article
- Comparison of Effect of Nebivolol and Bisoprolol on Sexual Function of Hypertensive Female Patients.Cureus · 2021Article
- RETRACTED: Investigation of the Potential of Nebivolol Hydrochloride-Loaded Chitosomal Systems for Tissue Regeneration: In Vitro Characterization and In Vivo Assessment.Pharmaceutics · 2021Article
- Effect of Low-Dose Nebivolol in Patients with Acute Myocardial Infarction: A Multi-Center Observational Study.Chonnam medical journal · 2020Article
- Gellan Gum-Based Hydrogel for the Transdermal Delivery of Nebivolol: Optimization and Evaluation.Polymers · 2019Article
- Nebivolol effect on doxorubicin-induced cardiotoxicity in breast cancer.Cancer management and research · 2018Article
- Protective effects of nebivolol from oxidative stress to prevent hypertension-related target organ damage.Journal of human hypertension · 2017Review
- Advancements in pharmacotherapy for angina.Expert opinion on pharmacotherapy · 2017Review
- Review
- Cardiovascular-related healthcare resource utilization and costs in patients with hypertension switching from metoprolol to nebivolol.American health & drug benefits · 2015Article
- The effect of AVE 0991, nebivolol and doxycycline on inflammatory mediators in an apoE-knockout mouse model of atherosclerosis.Medical science monitor : international medical journal of experimental and clinical research · 2012Article
- Heart rate control with adrenergic blockade: clinical outcomes in cardiovascular medicine.Vascular health and risk management · 2010Review
- Nebivolol (bystolic), a novel Beta blocker for hypertension.P & T : a peer-reviewed journal for formulary management · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nebivolol is a novel beta1-blocker with a greater degree of selectivity for beta1-adrenergic receptors than other agents in this class and a nitric oxide (NO)-potentiating, vasodilatory effect that is unique among beta-blockers currently available to clinicians (nebivolol is approved in Europe and is currently under review in the US). A NO-potentiating agent such as nebivolol may have an important role in hypertensive populations with reduced endothelial function such as diabetics, African-Americans and those with vascular disease. Nebivolol is a racemic mixture with beta-blocker activity residing in the d-isomer; in contrast, l-nebivolol is far more potent in facilitating NO release. Nebivolol is unique among beta-blockers in that, at doses < 10 mg, it does not inhibit the increase in heart rate normally seen with exercise. The efficacy ofnebivolol has been tested successfully in clinical trials against other agents including other beta-blockers, angiotensin-converting enzyme-inhibitors and calcium channel antagonists in patients with hypertension, angina, and congestive heart failure. The tolerability of nebivolol has been shown to be superior to that of atenolol and metoprolol. In controlled clinical trials, nebivolol has a side effect profile that is similar to placebo, in particular as it relates to fatigue and sexual dysfunction. This article will review published clinical data regarding this cardioselective beta-blocker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.